Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression

Not Applicable

Completed

Conditions: Depression

Interventions: Drug: escitalopram

First Posted Date: 2007-08-17

Last Posted Date: 2013-08-09

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 299

Registration Number: NCT00517764

Locations: 🇨🇦
Queens University, Kingston, Ontario, Canada
🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Escitalopram and Depression in Elderly Alzheimer's Patients

Phase 3

Terminated

Conditions: Depressive Disorder

First Posted Date: 2007-06-20

Last Posted Date: 2011-06-06

Lead Sponsor: University of British Columbia

Target Recruit Count: 50

Registration Number: NCT00488670

Locations: 🇨🇦
Mt. St. Joseph's Hospital, Vancouver, British Columbia, Canada
🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

Flushing in Social Anxiety Disorder on Cipralex

Phase 2

Completed

Conditions: Social Anxiety Disorder

Interventions: Drug: Placebo
Drug: Cipralex

First Posted Date: 2007-06-13

Last Posted Date: 2013-10-30

Lead Sponsor: START Clinic for Mood and Anxiety Disorders

Target Recruit Count: 71

Registration Number: NCT00485888

Locations: 🇨🇦
START Clinic for the Mood and Anxiety Disorders, Toronto,, Ontario, Canada

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Phase 2

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: placebo
Drug: pexacerfont
Drug: escitalopram

First Posted Date: 2007-06-01

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 260

Registration Number: NCT00481325

Locations: 🇺🇸
Us Clinical Research Centers, Llc, Costa Mesa, California, United States
🇺🇸
Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸
Pivotal Research Centers, Mesa, Arizona, United States

and more 47 locations

SSRI and Buprenorphine

Phase 3

Completed

Conditions: Opiate Dependence
Depression

Interventions: Drug: placebo
Drug: escitalopram

First Posted Date: 2007-05-21

Last Posted Date: 2012-04-03

Lead Sponsor: Butler Hospital

Target Recruit Count: 147

Registration Number: NCT00475878

Locations: 🇺🇸
Butler Hospital, Providence, Rhode Island, United States

Brain GABA Levels and Treatment Response in Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Escitalopram

First Posted Date: 2007-04-24

Last Posted Date: 2017-01-04

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT00464711

Locations: 🇺🇸
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States

Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment

Phase 4

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2007-04-23

Last Posted Date: 2009-09-21

Lead Sponsor: Nordfjord Psychiatric Centre

Target Recruit Count: 150

Registration Number: NCT00464191

Locations: 🇳🇴
Nordfjord Psychiatric Centre, Nordfjordeid, Norway

Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response

Phase 4

Completed

Conditions: Depression

First Posted Date: 2007-04-05

Last Posted Date: 2011-11-15

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 80

Registration Number: NCT00456430

Locations: 🇺🇸
Indiana University Adult Psychiatry Clinic, Indianapolis, Indiana, United States

Escitalopram in Schizophrenia in OCD- Open Label Study

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2007-04-05

Last Posted Date: 2009-01-27

Lead Sponsor: BeerYaakov Mental Health Center

Target Recruit Count: 15

Registration Number: NCT00456937

Locations: 🇮🇱
Beer Yaakov MHC, Beer Yaakov, Israel

Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

Not Applicable

Completed

Conditions: Depression

Interventions: Drug: Escitalopram
Drug: Desipramine

First Posted Date: 2007-04-04

Last Posted Date: 2019-03-19

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 37

Registration Number: NCT00456014

Locations: 🇺🇸
Columbia University/New York State Psychiatric Institute, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy